Beverly Wilshire Ltd. FY2025 Financial Results: Strong Turnaround and Capital Actions

Beverly Wilshire Ltd., a Singapore-listed healthcare and aesthetic medical group, has released its condensed interim consolidated financial statements for the year ended 31 December 2025. This review summarizes the key financial metrics, major year-over-year changes, capital actions, and the outlook for investors.

Key Financial Metrics and Performance Comparison

* Q3 2025 figures are inferred from half-year and annual data due to absence of explicit Q3 breakdowns.

Historical Performance Trends

• Revenue Growth: FY2025 revenue surged 60% YoY to S\$9.4 million, driven entirely by the Malaysian aesthetic medical and healthcare segment.
• Profitability Reversal: The Group returned to profitability with a net profit of S\$67,000 in FY2025, compared to a net loss of S\$5.8 million in FY2024, mainly due to higher revenue and significant reductions in impairments and administrative expenses.
• Gross Profit Margin: Improved from 52% in FY2024 to 56% in FY2025, reflecting better operating leverage and cost control.
• Net Asset Value: Swung from negative (-S\$5.3m) to positive S\$168,000, with NAV per share recovering from -0.844 cents to +0.015 cents, following equity fundraises and improved operations.

Exceptional Earnings and Expenses

• One-Off Impairments: Major impairments in FY2024 (S\$1.9m on property, plant and equipment and S\$1.3m on intangible assets) were not repeated in FY2025, resulting in a significant reduction of other losses.
• Lower Administrative Expenses: Down 23% YoY as a result of cost-cutting, mainly staff and professional fees.
• Marketing Spend: Distribution expenses increased substantially (from S\$147,000 to S\$1.18m) due to higher marketing agency fees, reflecting efforts to drive new growth.

Capital Actions and Share Dilution

• Share Issuance: The Company completed multiple share placements, raising capital through new shares for cash, debt conversions, and asset acquisitions. Share count increased from 632.9m to 1,152.0m (+82%), resulting in significant dilution but also a strengthened balance sheet.
• Major Asset Acquisition: 186.6m new shares were issued as part-payment for acquiring the second floor of Tower A, Nobel Healthcare Park.
• Debt Conversion: Debt of S\$754,000 and S\$60,000 was converted into equity in April and November 2025, respectively, further reducing liabilities and future cash outflows.
• Warrant Expiry: Some legacy warrants expired, reducing potential dilution risk going forward.

Dividends

• No dividend was declared or recommended for FY2025, in line with the previous year and reflecting the Group’s ongoing need to conserve cash for operations and growth initiatives.

Fundraising and Use of Proceeds

• The Group raised over S\$2 million through share subscriptions during the year. These funds were primarily allocated to working capital (manpower, professional fees, admin costs) and growth initiatives in the medical aesthetics business.

Balance Sheet and Cash Flows

• Current Assets: More than doubled to S\$4.4m, mainly due to a large deposit for the Nobel Healthcare Park asset acquisition.
• Current Liabilities: Fell sharply by 42% to S\$4.4m, due to debt conversions and reduced trade payables.
• Cash Flow: Net cash used in operations was S\$1.1m, reflecting working capital outflows (notably higher receivables and lower payables). Cash balance at year-end was S\$572,000, down from S\$858,000.

Chairman’s Statement and Outlook

“The Group will continue to broaden and deepen its market presence, elevate its service offerings and spearhead innovation. The Group will utilise its strengths, explore new opportunities, and stay current with industry trends, while continuing to launch new initiatives that will fuel growth and revolutionise customer experiences in the medical aesthetics industry.”

The tone is optimistic and forward-looking, emphasizing expansion, innovation, and capitalizing on sector growth trends in medical tourism and aesthetics. No material negative risks were highlighted by the Board.

Key Events and Risks

• Going Concern: The Board highlights improved financial footing due to recapitalization, debt conversions, and controlling shareholder support. Malaysian subsidiaries do not require further funding for the next 18 months, and the company expects to raise another S\$2 million through equity/debt, subject to approvals.
• Audit Disclaimer (FY2024): The previous year’s accounts had a disclaimer of opinion, mainly due to opening balances and going concern uncertainty. Management asserts that all audit issues have now been adequately disclosed and addressed.
• Related-Party Support: Dato’ Ng Tian Sang has provided an undertaking to support the Group’s cash flow for the next 18 months, ensuring continuity of operations.
• No Divestments, Legal Disputes, or Tax Changes: No such events were reported for FY2025.
• No Treasury Shares or Share Buybacks: The company had none outstanding at year-end.

Conclusion and Investment Recommendations

Overall Assessment: Beverly Wilshire Ltd. has staged a meaningful financial turnaround in FY2025, moving from a deep loss to a small net profit, and returning to positive equity. The business benefited from strong revenue growth in its core Malaysian aesthetics segment, robust cost controls, and a series of successful capital-raising and debt conversion activities that stabilized the balance sheet. However, the recovery is nascent, and the business remains thinly capitalized with ongoing operational cash needs and significant dilution from new share issues.

If You Currently Hold the Stock:

• Consider holding for now. The company has returned to profitability, completed its recapitalization, and is benefiting from favorable industry growth trends. However, ongoing monitoring is warranted due to continuing cash burn, no dividends, and the need for further fundraising.

If You Are Not Currently Holding the Stock:

• Exercise caution before entering. The fundamentals have improved, but the business model is sensitive to execution risks, and the company’s history of significant dilution could limit upside. Wait for evidence of sustained profitability, stronger cash flows, and successful integration of new assets before considering an investment.

Disclaimer: This analysis is based solely on the company’s published financial report for FY2025 and does not constitute investment advice. Investors should conduct their own due diligence and consider their risk tolerance before taking any action.

View B Wilshire Ltd Historical chart here